Investor Presentaiton

ODM-111 for acute and chronic pain Huge unmet need for non-opioid pain treatments - Orion among the frontrunners to target NaV1.8 Why are we targeting NaV1.8? NaV1.8 is validated ● target for pain ODM-111 is potent and selective NaV1.8 inhibitor ● Where are we now? Phase I ongoing No significant safety findings in SAD and MAD cohorts Detailed Phase I results to be reported later Next steps Plan to initiate phase II in acute pain in 2024 . Plan to initiate phase II in chronic pain in 2024 13 Investor Presentation Orion Corporation ORION

View entire presentation